Carnitine palmitoyltransferase 1A mRNA 3' untranslated region (CPT1A mRNA 3'UTR)

The Carnitine palmitoyltransferase 1A (CPT1A) mRNA 3' untranslated region (3'UTR) is a critical regulatory segment of the CPT1A transcript, which encodes the rate-limiting enzyme for mitochondrial fatty acid beta-oxidation (NCBI Gene: 1374). This region contains specific binding sites for microRNAs (miRNAs) and RNA-binding proteins that control the stability and translation efficiency of the mRNA (PubMed: 20543820). In metabolic disorders such as non-alcoholic fatty liver disease (NAFLD) and obesity, CPT1A expression is often suppressed by miRNAs like miR-33 and miR-370 binding to this 3'UTR, leading to impaired lipid metabolism (PubMed: 21655067, PubMed: 20303348). Conversely, in several cancers, including hepatocellular carcinoma, CPT1A is upregulated to facilitate fatty acid oxidation for energy, making its regulatory regions potential targets for therapeutic intervention (PubMed: 28611201). Therapeutic strategies targeting the CPT1A mRNA 3'UTR include antisense oligonucleotides (ASOs) and miRNA-based therapies designed to modulate protein levels (PubMed: 25193130). For example, antagomirs targeting miR-33 can indirectly increase CPT1A expression by preventing miRNA binding to the 3'UTR, thereby enhancing fatty acid oxidation (PubMed: 20543820). Monitoring biomarkers like CPT1A mRNA levels and plasma acylcarnitines is essential for evaluating the efficacy of these interventions. Overall, the CPT1A mRNA 3'UTR represents a sophisticated node for post-transcriptional metabolic control.

Other names

CPT1A 3'UTRCPT1-L mRNA 3'UTRCarnitine palmitoyltransferase 1A 3' untranslated region

Modulation of mRNA stability and translation through RNA interference or antisense-mediated degradation.